Stock Scorer

vTv Therapeutics Inc. (VTVT)

vTv Therapeutics Inc. reported revenue of 0 USD for the quarter ending 30 June 2026.

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than filled in. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD. The same series drawn ›

As last reported

The newest period the filing supports for each figure, in USD.
FigurePeriodAmountYear on year
Revenue Q2 '26 · ending 30 June 2026 0 —
Operating Income Q2 '26 · ending 30 June 2026 -13.9M —
Net Income Q2 '26 · ending 30 June 2026 -13.1M —
Operating Cash Flow Q2 '26 · ending 30 June 2026 -11.4M —
Free Cash Flow Q4 '23 · ending 31 December 2023 -2.9M —

Revenue and profit by financial year

As filed, in USD. A year the filing does not support is not listed.
YearEnding RevenueOperating IncomeNet IncomeFree Cash Flow
20252025-12-31 0-32.8M-27M—
20242024-12-31 1M-24.2M-18.5M-25.3M
20232023-12-31 0-25.5M-20.2M-19.1M
20222022-12-31 2M-22.5M-19.2M-16M
20212021-12-31 4M-21.7M-13M-19.3M
20202020-12-31 6.4M-11.9M-8.5M-18M
20192019-12-31 2.8M-20.9M-13M-23.1M
20182018-12-31 12.4M-19.8M-7.9M-26.9M
20172017-12-31 291K-50.7M-16.1M-44.6M
20162016-12-31 634K-55M-16.4M-48.3M

Every period

Revenue Quarterly

PeriodEndingRevenue
Q2 '262026-06-300
Q1 '262026-03-3136.8M
Q4 '252025-12-310
Q3 '252025-09-300
Q2 '252025-06-300
Q1 '252025-03-310
Q4 '242024-12-3117K
Q3 '242024-09-300
Q2 '242024-06-300
Q1 '242024-03-311M
Q4 '232023-12-310
Q3 '232023-09-300
Q2 '232023-06-300
Q1 '232023-03-310
Q4 '222022-12-319K
Q3 '222022-09-300
Q2 '222022-06-309K
Q1 '222022-03-312M
Q4 '212021-12-319K
Q3 '212021-09-303M

Operating Income Quarterly

PeriodEndingOperating Income
Q2 '262026-06-30-13.9M
Q1 '262026-03-3123.3M
Q4 '252025-12-31-7.9M
Q3 '252025-09-30-10.7M
Q2 '252025-06-30-7.7M
Q1 '252025-03-31-6.5M
Q4 '242024-12-31-4.9M
Q3 '242024-09-30-6.5M
Q2 '242024-06-30-7.2M
Q1 '242024-03-31-5.6M
Q4 '232023-12-31-4.7M
Q3 '232023-09-30-5.4M
Q2 '232023-06-30-8M
Q1 '232023-03-31-7.4M
Q4 '222022-12-31-6.3M
Q3 '222022-09-30-5.7M
Q2 '222022-06-30-4M
Q1 '222022-03-31-6.5M
Q4 '212021-12-31-11.1M
Q3 '212021-09-30-1.6M

Net Income Quarterly

PeriodEndingNet Income
Q2 '262026-06-30-13.1M
Q1 '262026-03-3124.1M
Q4 '252025-12-31-7.1M
Q3 '252025-09-30-8.7M
Q2 '252025-06-30-6M
Q1 '252025-03-31-5.1M
Q4 '242024-12-31-3.6M
Q3 '242024-09-30-4.8M
Q2 '242024-06-30-5.2M
Q1 '242024-03-31-4.9M
Q4 '232023-12-31-3.5M
Q3 '232023-09-30-6.7M
Q2 '232023-06-30-5.6M
Q1 '232023-03-31-4.5M
Q4 '222022-12-31-4.7M
Q3 '222022-09-30-4.3M
Q2 '222022-06-30-3.2M
Q1 '222022-03-31-7M
Q4 '212021-12-31-7.1M
Q3 '212021-09-30-1.1M

Operating Cash Flow Quarterly

PeriodEndingOperating Cash Flow
Q2 '262026-06-30-11.4M
Q1 '262026-03-319.2M
Q4 '252025-12-31-9.3M
Q3 '252025-09-30-5.2M
Q2 '252025-06-30-5.1M
Q1 '252025-03-31-5.7M
Q4 '242024-12-31-4.8M
Q3 '242024-09-30-6.4M
Q2 '242024-06-30-6.7M
Q1 '242024-03-31-7.3M
Q4 '232023-12-31-2.9M
Q3 '232023-09-30-4.8M
Q2 '232023-06-30-6.2M
Q1 '232023-03-31-5.2M
Q4 '222022-12-31-6.9M
Q3 '222022-09-30-8.8M
Q2 '222022-06-30706K
Q1 '222022-03-31-1M
Q4 '212021-12-31-6.4M
Q3 '212021-09-30-3.6M

Free Cash Flow Quarterly

Operating cash flow minus capital expenditure.

PeriodEndingFree Cash Flow
Q4 '232023-12-31-2.9M
Q3 '232023-09-30-4.8M
Q4 '222022-12-31-6.9M
Q3 '222022-09-30-8.8M
Q4 '212021-12-31-6.4M
Q3 '212021-09-30-3.6M
Q4 '182018-12-31-5.9M
Q4 '172017-12-31-6.3M
Q3 '172017-09-30-11.8M
Q2 '172017-06-30-12.6M
Q1 '172017-03-31-13.9M
Q4 '162016-12-31-11.4M
Q3 '162016-09-30-12.7M
Q4 '152015-12-31-9M
Q3 '152015-09-30-9.8M
Q2 '152015-06-30-8.8M
Q1 '152015-03-31-9.4M